Risperidone for treatment-refractory major depressive disorder: a randomized trial.
about
Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomesSecond-generation antipsychotics for major depressive disorder and dysthymiaChallenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved TherapeuticsPharmacological approaches to the challenge of treatment-resistant depressionSecond Generation Antipsychotics in the Treatment of Major Depressive Disorder: An UpdateEmerging targets for antidepressant therapiesNovel targets for antidepressant therapiesPharmacologic approaches to treatment resistant depression: a re-examination for the modern era.Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorderAugmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis.Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies.Use of atypical antipsychotics for treatment-resistant major depressive disorder.Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder.Therapeutic armamentarium for treating depression.If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.Use of risperidone as augmentation treatment for major depressive disorder.Therapeutic options in treatment-resistant depression.Targeting treatment-resistant depression.Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy.The integrative management of treatment-resistant depression: a comprehensive review and perspectives.Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled TrialsThe preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder.An investigation into aripiprazole's partial D₂ agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteersExtended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled stComparative effectiveness of monotherapy with mood stabilizers versus second generation (atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents.Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline.Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder.Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies.RISK OF NEW ONSET TYPE II DM IN MDD PATIENTS RECEIVING SECOND-GENERATION ANTIPSYCHOTICS TREATMENT: A NATIONWIDE COHORT STUDY.Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort
P2860
Q21144599-3A861169-F0B1-4932-B8D0-5FF5C5BB4471Q24235667-6F1875AF-30DE-44B5-BC97-19248A1C44F9Q26782997-61EC688E-32F7-453F-93B2-C21A96420C8DQ26798241-3AD5B449-2E40-4FBB-A230-00DB13EB6CC7Q28076712-B8F20A3F-4D59-43B0-B2C9-3EC67891DFBBQ28247614-ADF2BBBA-1EC4-4097-87AB-B97809929FE2Q28648254-3D0EF4BC-FA8D-4CA7-84F1-FEB89BF1D330Q33716723-8C960DC0-AE92-428B-952C-1FD007196E0DQ34010693-4B61E93B-EB32-48ED-A04A-80A9ABB64AE5Q34330761-462DC257-7F44-462C-B38D-D541A395BE1FQ36091234-8DCA3E8A-65ED-4DE5-9A1E-C991AC4920E8Q36275903-098372E4-2BC9-4C86-81C9-5E469270B862Q36588685-16436425-5ED2-4002-8B80-43F90DD2E723Q37101731-6BE73E09-53CA-4270-8BAB-14D754B41893Q37316104-6F533BE6-6000-414D-B0E3-3998F32E3854Q37734565-B40DB2DD-D49E-480F-AB76-EA02333D7405Q37777008-9057C032-EAE4-4AA9-8ADE-7B063B21DF01Q37822778-3B8BCC9D-31C4-4FEE-B371-17D8A038CF95Q37824372-612FA4B0-05BB-4672-9848-6B1ADA45B77BQ37881968-016815D4-1747-44C1-80F0-B73FD26E78A9Q37957770-46DA3C2D-71EC-4129-B7E9-3F3EF7B3E251Q38109589-1F9EF0D9-70AD-41CC-9560-5B470D311749Q38123516-12E715F5-BF99-437A-9309-49BD3FEA5C4EQ38125219-86B8FB33-D306-43E9-ACCD-962F4275B6C2Q38157027-13D2EA91-480E-4078-8D30-A870F665C7CCQ38181363-38F4757D-374B-4CFA-88CA-C7DD9AF2FB7AQ38377259-A056C904-C0F6-41C0-B892-4D90C4562C71Q38674314-01783FDB-9500-4CC6-A3AE-A96B0BDB90DEQ39837691-EE49DB7F-8874-477E-BA7C-D593546C351EQ43153951-C35CE911-E127-4527-A9CD-068B0D48FFEAQ43938311-0543A507-018B-4665-A9D3-E5E18E6AA9A4Q46358244-21B1B490-2BAD-42D6-8542-2591471A4DF7Q46382585-33137489-171F-4942-AB00-62C638EDD9D4Q47147496-45394BBE-8D9C-4674-9FFC-95B8D000631EQ47557944-3119B6BE-C746-4A95-847F-3EE176D0A4BBQ48060784-1DC3BF77-A1CE-466F-8731-7BEC9E22A55BQ58782266-E2D49ED9-5A9D-4037-988F-7CBB6D1355E9
P2860
Risperidone for treatment-refractory major depressive disorder: a randomized trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Risperidone for treatment-refractory major depressive disorder: a randomized trial.
@en
Risperidone for treatment-refractory major depressive disorder: a randomized trial.
@nl
type
label
Risperidone for treatment-refractory major depressive disorder: a randomized trial.
@en
Risperidone for treatment-refractory major depressive disorder: a randomized trial.
@nl
prefLabel
Risperidone for treatment-refractory major depressive disorder: a randomized trial.
@en
Risperidone for treatment-refractory major depressive disorder: a randomized trial.
@nl
P2093
P1476
Risperidone for treatment-refractory major depressive disorder: a randomized trial.
@en
P2093
Carla M Canuso
Colette Kosik-Gonzalez
Gahan J Pandina
Georges M Gharabawi-Garibaldi
Ibrahim Turkoz
Mary J Kujawa
Ramy A Mahmoud
P304
P356
10.7326/0003-4819-147-9-200711060-00003
P407
P577
2007-11-01T00:00:00Z